Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

BCOR (BCL6 Corepressor)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3
KMT2C mutation + BCOR mutation + KDM5C mutation	Non Small Cell Lung Cancer	KMT2C mutation + BCOR mutation + KDM5C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BCOR mutation	Non Small Cell Lung Cancer	BCOR mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H	Non Small Cell Lung Cancer	KMT2C mutation + BCOR mutation + KDM5C mutation + TMB-H	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression	Non Small Cell Lung Cancer	KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
BCOR mutation	Acute Myelogenous Leukemia	BCOR mutation	Acute Myelogenous Leukemia	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3	HAG + azacitidine Sensitive: C3 – Early Trials HAG + azacitidine Sensitive : C3
BCOR mutation	Gastrointestinal Cancer	BCOR mutation	Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma	MYB-NFIB fusion + BCOR F1106Tfs5 + BCOR L1524Hfs8	Adenoid Cystic Carcinoma	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies anlotinib + eribulin mesylate Sensitive : C4	anlotinib + eribulin mesylate Sensitive: C4 – Case Studies anlotinib + eribulin mesylate Sensitive : C4
BCOR L1524Hfs*8	Adenoid Cystic Carcinoma	BCOR L1524Hfs*8	Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4
BCOR F1106Tfs*5	Adenoid Cystic Carcinoma	BCOR F1106Tfs*5	Adenoid Cystic Carcinoma	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4	anlotinib Sensitive: C4 – Case Studies anlotinib Sensitive : C4